Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients | WAPE

Newsbenzinga

Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients

Jul 1, 2026, 10:13 ET · Published

Article summary

Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.

An excerpt from the original article.

Related companies

CANFCANFView stock

Comments —

Comment

Loading comments…